Skip to content
Search AI Powered

Latest Stories

Manufacturing halted in 40 Indian pharma firms following inspection of 162 companies: Health Minister

The Indian government has suspended manufacturing in over 40 pharma companies based on a risk-based assessment conducted earlier in the year across 162 firms, according to the data provided by Union Health Minister Mansukh Mandaviya in Parliament on Thursday (Aug. 10).

“Overall, a sum of 143 show-cause notices has been issued,” Mandaviya said.


There have been numerous recent incidents involving accusations from foreign countries regarding the contamination of syrups, eye drops, and ointments manufactured in India. Countries such as the Gambia, Uzbekistan, and Cameroon have linked the deaths of 70, 18, and six children, respectively, to cough syrups contaminated in India.

Licenses for specific products have been either temporarily suspended or fully revoked for an additional 66 companies.  In one case, an FIR has been registered, and in 21 cases, warning letters have been issued following inspections by both the Central Drugs Standard Control Organization and State authorities, the Minister added.

Meanwhile, the Indian government has mandated rigorous testing for cough syrups before export. Starting June 1, any cough syrup must possess a government laboratory-issued certificate of analysis before being exported, the government said in a notice dated May 22.

Good manufacturing practices

The Health Minister recently met with representatives from pharmaceutical companies in the MSME sector and underscored the importance of self-regulation in drug manufacturing to maintain quality standards.

The Minister also encouraged pharmaceutical firms to embrace Good Manufacturing Processes (GMP) in drug manufacturing, aligning with international standards set by the World Health Organization. Currently, just 2,000 out of India's 10,500 manufacturing units adhere to these standards, the Minister said.

Pharmaceutical sector experts support the implementation of the new GMP outlined in a 2018 draft of Schedule M, noting it will not only enhance the quality of exported drugs but also establish the same standard within India.

The government has firmly instructed larger pharmaceutical companies, with a turnover exceeding £29 million (Rs 250 crore), to adopt these measures within six months, while smaller firms are granted a year for compliance.

‘3% of medicines deemed substandard’

In the July parliamentary session, Bharati Pravin Pawar, Minister of State for Health, revealed that "out of the total 84,874 drug samples tested in 2020-21, 2,652 samples (3.12 per cent) were deemed substandard, and 263 samples (0.31 per cent) were identified as spurious and adulterated drugs."

The Minister emphasised on various regulatory measures taken to ensure medicine quality, which include notifications mandating the inclusion of barcodes or quick response codes in active pharmaceutical ingredients and specific drug formulations.

Furthermore, “drug marketers are now accountable for their product quality under a notification. Central drug testing labs were reinforced, and the Drugs and Cosmetics Rules were amended to require stability proof and excipient safety for manufacturing licenses,” she said.

The Central government allocated over £61 million (Rs 647.47 crore) to enhance the drug regulatory system, upgrading labs, setting up new testing facilities, and improving state drug control offices, the Minister added.

Health authorities are investigating an allegation that a local pharmaceutical regulator in Haryana facilitated the substitution of cough syrup samples, potentially linked by the World Health Organization (WHO) to children's deaths in Gambia, for testing at an Indian laboratory, reportedly in exchange for a bribe.

India's expansive pharma basket

India presently holds a 5.92 per cent stake in the global pharmaceutical and drug market. Despite challenges, the country’s pharmaceutical exports have sustained their upward trajectory, amounting to $25.3 billion for the fiscal year 2022-23, according to data from the Pharmaceuticals Export Promotion Council of India (Pharmexcil), a division of the Ministry of Commerce and Industry.

India dominates vaccine export, meeting 65-70 per cent of WHO's demand, recent data showed. The country’s exports consist of formulations and biologics, accounting for 73.31 per cent, followed by drug intermediates and bulk drugs. Of the global generics, eight in twenty are Indian, with over 55 per cent of exports focused on regulated markets.

“Despite varying growth rates throughout the year, marked by growth in eight months and a decline in four, the industry still achieved a 3.25 per cent increase from the previous fiscal year's $24.5 billion,” said Ravi Udaya Bhaskar, Director General of Pharmexcil. “The U.S., Belgium, South Africa, the UK, and Brazil remained the top five pharma importers.”

The U.S., India's largest pharmaceutical products exporter, also reported three deaths linked to bacterial contaminants in over-the-counter eye drops manufactured in India.

In 2021-22, the U.S., the UK, and Russia were prominent importers of Indian pharmaceutical products, representing 29 per cent, 3 per cent, and 2.4 per cent respectively. India's pharmaceutical exports to these nations were as outlined: the U.S. at $7,101.6 million, the UK at $704.5 million, South Africa at $612.3 million, Russia at $597.8 million, and Nigeria at $588.6 million.

More For You

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Prakash Patel was speaking at a panel discussion at the Sigma Conference

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Pharmacists need to be a part of integrated care boards (ICB) to stop GPs from monopolising services based on their needs rather than the needs of the patient, according to Prakash Patel, Community Pharmacy Engaland (CPE) representative for North London.

“The evolution of the NHS should mean there can be no decision of pharmacy without pharmacist,” Patel told delegates at the Sigma Pharmacy Conference in Baku, Azerbaijan on Tuesday.

Keep ReadingShow less
David Webb
David Webb, NHS England's Chief Pharmaceutical Officer
David Webb, NHS England's Chief Pharmaceutical Officer

Sigma Conference: "Community pharmacy ready to make a profound contribution to 10 Year Health Plan," says David Webb

A national community pharmacy prescribing service remains a long-term goal of the government, according to NHS chief pharmaceutical officer, David Webb.

The Labour Party in its election manifesto last year said it would “create a Community Pharmacist Prescribing Service, granting more pharmacists independent prescribing rights”.

Keep ReadingShow less
New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less